Corcept Therapeutics Incorporated (CORT)
Automate Your Wheel Strategy on CORT
With Tiblio's Option Bot, you can configure your own wheel strategy including CORT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
Published: April 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Corcept (CORT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.
Read More
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Published: April 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, April 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 21, 2026.
Read More
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORT
Published: April 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”), of the important April 21, 2026 lead plaintiff deadline.
Read More
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Published: April 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”).
Read More
Corcept (CORT) Class Action Alleges Misstatements on FDA Data Concerns - Hagens Berman
Published: April 01, 2026 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026. The firm urges Corcept investors who suffered significant losses to contact the firm now to discuss their rights.
Read More
Bragar Eagel & Squire, P.C. Urges Navan and Corcept Investors with Large Losses to Contact the Firm Before the Upcoming Lead Plaintiff Deadlines
Published: March 31, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Navan, Inc. (NASDAQ: NAVN) and Corcept Therapeutics Incorporated (NASDAQ: CORT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Read More
CORT INVESTOR ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Published: March 30, 2026 by: PRNewsWire
Sentiment: Neutral
Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 Deadline SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026. The firm urges Corcept investors who suffered significant losses to contact the firm now to discuss their rights.
Read More
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Published: March 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 30, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 21, 2026.
Read More
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Published: March 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 27, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026. The firm urges Corcept investors who suffered significant losses to contact the firm now to discuss their rights.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
Published: March 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Corcept (CORT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.
Read More
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics Incorporated Securities Class Action Lawsuit — The Gross Law Firm
Published: March 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT).
Read More
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
Published: March 25, 2026 by: Reuters
Sentiment: Positive
Corcept Therapeutics shares jumped more than 32% to nearly a two-month high on Wednesday after the U.S. health regulator approved its lead drug for treating an aggressive form of ovarian cancer that no longer responds to standard treatment.
Read More
FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
Published: March 25, 2026 by: Business Wire
Sentiment: Neutral
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epitheli.
Read More
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: March 24, 2026 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa., March 24, 2026 /PRNewswire/ -- The Law Offices of Howard G.
Read More
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Published: March 24, 2026 by: PRNewsWire
Sentiment: Neutral
Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 Deadline SAN FRANCISCO, March 24, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026. The firm urges Corcept investors who suffered significant losses to contact the firm now to discuss their rights.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
Published: March 24, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Corcept (CORT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.
Read More
Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately
Published: March 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed against on behalf of all persons and entities that purchased or otherwise Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept” or the ‘Company”) securities between October 31, 2024 and December 30, 2025, both dates inclusive (the "Class Period"). Investors have until April 21, 2026, to seek appointments as lead plaintiff.
Read More
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Published: March 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 23, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 21, 2026.
Read More
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Published: March 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 23, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026. The firm urges Corcept investors who suffered significant losses to contact the firm now to discuss their rights.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
Published: March 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Corcept (CORT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.
Read More
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Published: March 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 19, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”).
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines - CORT
Published: March 19, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
CORT Shareholder Notice: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Published: March 18, 2026 by: PRNewsWire
Sentiment: Neutral
Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 Deadline SAN FRANCISCO, March 18, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026. The firm urges Corcept investors who suffered significant losses to contact the firm now to discuss their rights.
Read More
Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 06, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and certain of its top executives. The lawsuit, Allegheny County Employees' Retirement System v.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Corcept (CORT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.
Read More
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 21, 2026.
Read More
Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
Published: March 05, 2026 by: PRNewsWire
Sentiment: Neutral
Lawsuit Alleges Corcept Ignored Repeated FDA Warnings Against Filing Relacorilant NDA; Stock Plunged 50% on Revealed "Evidence Gaps" SAN FRANCISCO, March 5, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and certain of its top executives. The lawsuit, Allegheny County Employees' Retirement System v.
Read More
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Published: March 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”).
Read More
Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead?
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Neutral
CORT's Korlym 2025 sales rises 13% Y/Y, with 2026 revenues seen at $900M-$1B. However, the court ruling favoring Teva's generic may put pressure on future sales.
Read More
Law Offices of Frank R. Cruz Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action
Published: March 04, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action.
Read More
About Corcept Therapeutics Incorporated (CORT)
- IPO Date 2004-04-14
- Website https://www.corcept.com
- Industry Biotechnology
- CEO Joseph K. Belanoff
- Employees 500